Aberdeen Fertility Centre, NHS Grampian and University of Aberdeen, Aberdeen, UK.
Clinical Trials Unit National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Health Technol Assess. 2022 May;26(25):1-142. doi: 10.3310/AEFU1104.
Freezing all embryos, followed by thawing and transferring them into the uterine cavity at a later stage (freeze-all), instead of fresh-embryo transfer may lead to improved pregnancy rates and fewer complications during in vitro fertilisation and pregnancies resulting from it.
We aimed to evaluate if a policy of freeze-all results in a higher healthy baby rate than the current policy of transferring fresh embryos.
This was a pragmatic, multicentre, two-arm, parallel-group, non-blinded, randomised controlled trial.
Eighteen in vitro fertilisation clinics across the UK participated from February 2016 to April 2019.
Couples undergoing their first, second or third cycle of in vitro fertilisation treatment in which the female partner was aged < 42 years.
If at least three good-quality embryos were present on day 3 of embryo development, couples were randomly allocated to either freeze-all (intervention) or fresh-embryo transfer (control).
The primary outcome was a healthy baby, defined as a live, singleton baby born at term, with an appropriate weight for their gestation. Secondary outcomes included ovarian hyperstimulation, live birth and clinical pregnancy rates, complications of pregnancy and childbirth, health economic outcome, and State-Trait Anxiety Inventory scores.
A total of 1578 couples were consented and 619 couples were randomised. Most non-randomisations were because of the non-availability of at least three good-quality embryos ( = 476). Of the couples randomised, 117 (19%) did not adhere to the allocated intervention. The rate of non-adherence was higher in the freeze-all arm, with the leading reason being patient choice. The intention-to-treat analysis showed a healthy baby rate of 20.3% in the freeze-all arm and 24.4% in the fresh-embryo transfer arm (risk ratio 0.84, 95% confidence interval 0.62 to 1.15). Similar results were obtained using complier-average causal effect analysis (risk ratio 0.77, 95% confidence interval 0.44 to 1.10), per-protocol analysis (risk ratio 0.87, 95% confidence interval 0.59 to 1.26) and as-treated analysis (risk ratio 0.91, 95% confidence interval 0.64 to 1.29). The risk of ovarian hyperstimulation was 3.6% in the freeze-all arm and 8.1% in the fresh-embryo transfer arm (risk ratio 0.44, 99% confidence interval 0.15 to 1.30). There were no statistically significant differences between the freeze-all and the fresh-embryo transfer arms in the live birth rates (28.3% vs. 34.3%; risk ratio 0.83, 99% confidence interval 0.65 to 1.06) and clinical pregnancy rates (33.9% vs. 40.1%; risk ratio 0.85, 99% confidence interval 0.65 to 1.11). There was no statistically significant difference in anxiety scores for male participants (mean difference 0.1, 99% confidence interval -2.4 to 2.6) and female participants (mean difference 0.0, 99% confidence interval -2.2 to 2.2) between the arms. The economic analysis showed that freeze-all had a low probability of being cost-effective in terms of the incremental cost per healthy baby and incremental cost per live birth.
We were unable to reach the original planned sample size of 1086 and the rate of non-adherence to the allocated intervention was much higher than expected.
When efficacy, safety and costs are considered, freeze-all is not better than fresh-embryo transfer.
This trial is registered as ISRCTN61225414.
This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 26, No. 25. See the NIHR Journals Library website for further project information.
与新鲜胚胎移植相比,将所有胚胎冷冻,随后在稍后阶段解冻并移植到子宫腔中(冻融)可能会提高体外受精和由此产生的妊娠的妊娠率并减少并发症。
我们旨在评估冷冻所有胚胎的策略是否比当前的新鲜胚胎移植策略能产生更高的健康婴儿率。
这是一项务实的、多中心、两臂、平行组、非盲、随机对照试验。
英国 18 家体外受精诊所于 2016 年 2 月至 2019 年 4 月参与。
年龄<42 岁的女性伴侣进行第一次、第二次或第三次体外受精治疗的夫妇。
如果在胚胎发育的第 3 天有至少 3 个优质胚胎,则夫妇被随机分配到冷冻所有(干预)或新鲜胚胎移植(对照)。
主要结局是健康婴儿,定义为足月出生的活产婴儿,胎龄适当。次要结局包括卵巢过度刺激、活产和临床妊娠率、妊娠和分娩并发症、健康经济学结局和状态-特质焦虑量表评分。
共有 1578 对夫妇同意,其中 619 对夫妇被随机分组。大多数非随机分组是因为至少没有 3 个优质胚胎可用(=476)。在随机分组的夫妇中,有 117 对(19%)未遵守分配的干预措施。在冷冻所有组中,不遵守的比例更高,主要原因是患者选择。意向治疗分析显示,冷冻所有组的健康婴儿率为 20.3%,新鲜胚胎移植组为 24.4%(风险比 0.84,95%置信区间 0.62 至 1.15)。使用遵从平均因果效应分析(风险比 0.77,95%置信区间 0.44 至 1.10)、方案分析(风险比 0.87,95%置信区间 0.59 至 1.26)和实际治疗分析(风险比 0.91,95%置信区间 0.64 至 1.29)也得到了类似的结果。卵巢过度刺激的风险在冷冻所有组为 3.6%,新鲜胚胎移植组为 8.1%(风险比 0.44,99%置信区间 0.15 至 1.30)。在活产率(28.3% 对 34.3%;风险比 0.83,99%置信区间 0.65 至 1.06)和临床妊娠率(33.9% 对 40.1%;风险比 0.85,99%置信区间 0.65 至 1.11)方面,冷冻所有组和新鲜胚胎移植组之间没有统计学显著差异。在男性参与者(平均差异 0.1,99%置信区间-2.4 至 2.6)和女性参与者(平均差异 0.0,99%置信区间-2.2 至 2.2)之间,手臂之间的焦虑评分没有统计学显著差异。经济分析表明,就每个健康婴儿的增量成本和每个活产的增量成本而言,冷冻所有在成本效益方面不太可能具有优势。
我们无法达到最初计划的 1086 例样本量,而且不遵守分配干预的比例远高于预期。
就疗效、安全性和成本而言,冷冻所有并不优于新鲜胚胎移植。
该试验由英国国家卫生与保健研究所(NIHR)健康技术评估计划资助,并将在;第 26 卷,第 25 期。有关该项目的更多信息,请参见 NIHR 期刊库网站。